siRNA targeting glycolate oxidase (HAO1)
Lumasiran
Brand names: Oxlumo
Adult dose
Dose: Weight-based SC monthly for 3 doses then quarterly maintenance
Route: SC
Frequency: monthly then q3m
Clinical pearls
- Primary hyperoxaluria type 1 — specialist metabolic/nephrology
Contraindications
- Hypersensitivity
Side effects
- Injection site reactions
- Abdominal pain
Monitoring
- Urinary oxalate
- Renal function
Reference: BNF; NICE HST; SmPC; https://bnf.nice.org.uk/drugs/lumasiran/. Verify against your local formulary and the latest BNF before prescribing.